Results 281 to 290 of about 106,112 (301)

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

International Journal of Antimicrobial Agents, 2020
Chi Zhang, Zhao Wu, Hong Zhao
exaly  

Tocilizumab–Conjugated Polymer Nanoparticles for NIR‐II Photoacoustic‐Imaging‐Guided Therapy of Rheumatoid Arthritis

Advanced Materials, 2020
Ji Qi, Chao Chen, Liang Song
exaly  

Tocilizumab treatment in COVID‐19: A single center experience

Journal of Medical Virology, 2020

exaly  

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Lancet Rheumatology, The, 2020
Giovanni Guaraldi, Marianna Meschiari, Alessandro Cozzi-Lepri   +2 more
exaly  

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

New England Journal of Medicine, 2021
Reena Shah
exaly  

Tocilizumab

Reactions Weekly
  +4 more sources

Tocilizumab

Reactions Weekly, 2016
openaire   +2 more sources

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy

Autoimmunity Reviews, 2020
Simone Piva, Marco Cattalini, Emirena Garrafa   +2 more
exaly  

Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial

Lancet Respiratory Medicine,the, 2021
Dhruva Chaudhry, Vikas Agarwal, Athimalaipet V Ramanan   +2 more
exaly  

Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial

Lancet Neurology, The, 2020
Chao Zhang, Wei Qiu, Xinghu Zhang
exaly